Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

22.71 +0.32 (+1.43%)
Streaming Delayed Price Updated: 10:43 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind. 
Via Benzinga
Topics ETFs
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Via Benzinga
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk. Study estimates 7-9 excess GBS cases per million doses. 
Via Benzinga
Exposures Product Safety
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
Via The Motley Fool
Investing $50,000 in Each of These 5 Stocks Could Make You Nearly $17,500 in Passive Income in 2025
Via The Motley Fool
Is Pfizer Stock Undervalued at Current Prices?
Via The Motley Fool
Should You Buy Pfizer Stock Right Now in 2025?
Via The Motley Fool
How Is The Market Feeling About Pfizer?
Via Benzinga
Warren Buffett's Warning to Wall Street Reached Deafening Proportions in 2024. Here's What to Do as 2025 Gets Started.
Via The Motley Fool
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Pfizer Antiviral Paxlovid's Extended Use Shows Mixed Results for Long COVID Relief: Study
A patient-led study examines the potential of extended Paxlovid courses for Long COVID relief, documenting varied outcomes and emphasizing the need for clinical trials. 
Via Benzinga
Exposures COVID-19
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
25 Top Dividend Stocks to Buy and Hold in 2025
Via The Motley Fool
Time to Dump or Double Up on SCHD?
SCHD shares have fallen nearly 10% in a month. 
Via The Motley Fool
AskSlim Market Week - Friday, Jan. 3
An analysis and commentary on the financial markets. 
Via Talk Markets
Topics Futures Stocks / Equities
3 Ultra-High-Yield Dividend Stocks That Are Screaming Buys in 2025
Three high-octane income stocks -- sporting an average yield of 7.93% -- can fatten investors' pocketbooks in the new year. 
Via The Motley Fool
10 Magnificent Stocks That Can Make You Richer in 2025
A new year brings with it new opportunities to grow your wealth on Wall Street. 
Via The Motley Fool
Got $5,000? These 3 Stocks Are Absurdly Cheap Buys Heading Into 2025
Via The Motley Fool
Top 3 Stocks Seeing a Spike in Call Option Volume
Three stocks reported unusual call option volume this month, and the reasons why would make sense to all investors and Wall Street analysts. 
Via MarketBeat
Topics ETFs
10 Stock Market Predictions for 2025
Here's what to expect from the stock market, along with some of Wall Street's hottest trends and most influential businesses, in the new year. 
Via The Motley Fool
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet
Via Benzinga
Exposures Fossil Fuels
US Stocks Open Higher; House Prices Increase In October
Via Benzinga
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results. 
Via Benzinga
3 Reasons to Buy Pfizer Stock Like There's No Tomorrow
The beaten-down pharmaceutical giant could double your investment over three to four years. 
Via The Motley Fool
Pfizer: 4 Reasons to Buy This Stock
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something ca 
Via MarketBeat
Exposures COVID-19
Sangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s Cautious
Sangamo intends to explore all options to advance the program, 
Via Stocktwits
5 Unbeatable Stocks I'm Eager to Buy in 2025
These value, growth, and income stocks are incredibly cheap in a historically pricey stock market. 
Via The Motley Fool
My 5 Favorite Ultra-High-Yield Dividend Stocks to Buy for 2025
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.